Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Dermatologic 5Other hematologic neoplasm 2Genitourinary 2Gastrointestinal 2Lymphoid 1Classical hematology 1Breast 1

Conditions

Fatigue 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 692Paclitaxel 678Cyclophosphamide 634Docetaxel 553Capecitabine 467Letrozole 407Carboplatin 392Fulvestrant 377Doxorubicin 330Tamoxifen 288pembrolizumab 270Anastrozole 252Epirubicin 249exemestane 238pertuzumab 226Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Infliximab × Breast × Clear all
NCT00112749 2020-07-31

Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Fatigue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡